Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Aug 25:16:147.
doi: 10.1186/s12882-015-0144-z.

The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial

Davina J Tai  1 , Kelvin Leung  2 , Pietro Ravani  3   4 , Robert R Quinn  5   6 , Nairne Scott-Douglas  7 , Jennifer M MacRae  8 ; Alberta Kidney Disease Network
Affiliations
Randomized Controlled Trial

The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial

Davina J Tai et al. BMC Nephrol. .

Abstract

Background: Unfractionated heparin is the most common anticoagulant used in haemodialysis (HD), although it has many potential adverse effects. Citrate dialysate (CD) has an anticoagulant effect which may allow reduction in cumulative heparin dose (CHD) compared to standard acetate dialysate (AD).

Methods: This double-blinded, randomised, cross-over trial of chronic haemodialysis patients determines if CD allows reduction in CHD during HD compared with AD. After enrolment, intradialytic heparin is minimised during a two-week run-in period using a standardised protocol based on a visual clotting score. Patients still requiring intradialytic heparin after the run-in period are randomised to two weeks of HD with AD followed by two weeks of CD (Sequence 1) or two weeks of HD with CD followed by two weeks of AD (Sequence 2). The primary outcome is the change in CHD with CD compared with AD. Secondary outcomes include metabolic and haemodynamic parameters, and dialysis adequacy.

Discussion: This randomised controlled trial will determine the impact of CD compared with AD on CHD during HD.

Trial registration: ClinicalTrials.gov NCT01466959.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study Flow Diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178–189. doi: 10.1111/j.1542-4758.2007.00166.x. - DOI - PubMed
    1. Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012;60(3):473–486. doi: 10.1053/j.ajkd.2012.03.017. - DOI - PMC - PubMed
    1. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwiec M. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol. 2004;24(1):154–161. doi: 10.1159/000076244. - DOI - PubMed
    1. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial. 2010;23(5):510–515. doi: 10.1111/j.1525-139X.2010.00770.x. - DOI - PMC - PubMed
    1. Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis. 2008;51(5):789–795. doi: 10.1053/j.ajkd.2007.12.040. - DOI - PubMed

Publication types

Associated data